Patents by Inventor Thomas Albert Engler

Thomas Albert Engler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors
    Patent number: 9624218
    Abstract: Pyrido[2,3-d]pyrimidin-4-one compounds, formulations containing those compounds, and their use as tankyrase 1 and 2 inhibitors Formula (I).
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: April 18, 2017
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Hisham Omer Eissa, Thomas Albert Engler, Kelly Wayne Furness, Kenneth B. Rank, Timothy Andrew Woods, Aaron D. Wrobleski
  • PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS
    Publication number: 20160251348
    Abstract: Pyrido[2,3-d]pyrimidin-4-one compounds, formulations containing those compounds, and their use as tankyrase 1 and 2 inhibitors Formula (I).
    Type: Application
    Filed: October 29, 2014
    Publication date: September 1, 2016
    Inventors: Marcio CHEDID, Hisham Omer EISSA, Thomas Albert ENGLER, Kelly Wayne FURNESS, Kenneth B. RANK, Timothy Andrew WOODS, Aaron D. WROBLESKI
  • Potentiation of cancer chemotherapy by 7-(2, 5-dihydro-4-imidazo [1, 2-a] pyridine-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro -2-(1-piperidinyl-carbonyl)-pyrrolo [3,2,1-jk] [1,4] benzodiazepine
    Patent number: 8648063
    Abstract: An improved method for treating gastric cancer, ovarian cancer, non-small cell lung cancer, or colorectal cancer in a patient is described, as well as pharmaceutical compositions useful for the method and a process for preparing said compositions.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: February 11, 2014
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Thomas Albert Engler
  • Potentiation of cancer chemotherapy by 7-(2, 5-dihydro-4-imidazo [1, 2-A] pyridine-3-yl-2,5-Dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyl)-pyrrolo [3,2,1-jk] [1,4] benzodiazepine
    Patent number: 8318713
    Abstract: A method for treating gastric cancer, ovarian cancer, non-small cell lung cancer, or colorectal cancer in a patient is described, as well as pharmaceutical compositions comprising 7-(2,5-dihydro-4-imidazo[1,2-a]pyridine-3-yl-2,5-dioxo-IH-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinyl-carbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine, useful for the method and a process for preparing said compositions.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: November 27, 2012
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Thomas Albert Engler
  • PURINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20110294792
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: August 9, 2011
    Publication date: December 1, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Purine derivatives as kinase inhibitors
    Patent number: 8058425
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: November 15, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Purine derivatives as kinase inhibitors
    Patent number: 8022065
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: September 20, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, James Robert Henry, Sushant Malhotra, Jon Kevin Reel
  • PURINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20110207721
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: May 4, 2011
    Publication date: August 25, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • POTENTIATION OF CANCER CHEMOTHERAPY BY 7-(2, 5- DIHYDRO- 4-IMIDAZO [1, 2-A] PYRIDINE-3-YL-2,5-DIOXO-IH-PYRROL-3-YL)-9-FLUORO-1,2,3,4 TETRAHYDRO -2-(1-PIPERIDINYL-CARBONYL)-PYRROLO [3,2,1-JK] [1,4] BENZODIAZEPINE
    Publication number: 20100166884
    Abstract: A method for treating gastric cancer, ovarian cancer, non-small cell lung cancer, or colorectal cancer in a patient is described, as well as pharmaceutical compositions comprising 7-(2,5-dihydro-4-imidazo[1,2-a]pyridine-3-yl-2,5-dioxo-IH-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinyl-carbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine, useful for the method and a process for preparing said compositions.
    Type: Application
    Filed: June 20, 2008
    Publication date: July 1, 2010
    Inventors: Aktham Aburub, Marcio Chedid, Thomas Albert Engler, Venkatraghavan Vasudevan
  • PURINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20090105229
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: December 12, 2008
    Publication date: April 23, 2009
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel
  • TGF-? inhibitors
    Patent number: 7511056
    Abstract: The present invention is directed to inhibitors of TGF-? of Formula I:
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: March 31, 2009
    Assignee: Eli Lilly and Company
    Inventors: Clive Gideon Diefenbacher, Thomas Albert Engler, Hong-Yu Li, Sushant Malhotra, Jason Scott Sawyer, Yan Wang
  • Purine derivatives as kinase inhibitors
    Patent number: 7491716
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: February 17, 2009
    Assignee: Eli Lilly and Company
    Inventor: Thomas Albert Engler
  • Tgf-Beta Inhibitors
    Publication number: 20080262004
    Abstract: The present invention is directed to inhibitors of TGF-? of Formula I:
    Type: Application
    Filed: November 2, 2005
    Publication date: October 23, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Clive Gideon Diefenbacher, Thomas Albert Engler, Hong-Yu Li, Sushant Malhotra, Jason Scott Sawyer, Yan Wang
  • Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors
    Patent number: 7405305
    Abstract: The present invention provides kinase inhibitors of Formula (I)
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: July 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Pamela Ann Albaugh, Jochen Ammenn, Timothy Paul Burkholder, Joshua Ryan Clayton, Scott Eugene Conner, Brian Eugene Cunningham, Thomas Albert Engler, Kelly Wayne Furness, James Robert Henry, Sushant Malhotra, Mark Joseph Tebbe, Guoxin Zhu, YiHong Li, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Compounds as pharmaceutical agents
    Patent number: 7405299
    Abstract: The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: July 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Todd Vincent Decollo, Alexander Glenn Godfrey, Charles Raymond Heap, Chi-Hsin Richard King, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Yan Wang, Clive Gideon Diefenbacher, Thomas Albert Engler, Sushant Malhotra, Sreenivasa Reedy Mundla
  • Methods and compounds for treating proliferative diseases
    Patent number: 7109229
    Abstract: The compounds disclosed herein are indolocarbazoles of Formula (I), which are potent CDK4 inhibitors, and are useful in the treatment of cell proliferative disorders, including cancer. Formula (I).
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: September 19, 2006
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, Kelly Wayne Furness, Sushant Malhotra, Stephen Lyle Briggs, Harold Burns Brooks, David K yes Clawson, Concepcion Sanchez-Martinez, Faming Zhang, Guoxin Zhu
  • Methods and compounds for treating proliferative diseases
    Publication number: 20040048915
    Abstract: The compounds disclosed herein are indolocarbazoles of Formula (I), which are potent CDK4 inhibitors, and are useful in the treatment of cell proliferative disorders, including cancer. Formula (I).
    Type: Application
    Filed: February 7, 2003
    Publication date: March 11, 2004
    Inventors: Thomas Albert Engler, Kelly Wayne Furness, Sushant Malhotra, Stephen Lyle Briggs, Harold Burns Brooks, David Keyes Clawson, Concepcion Sanchez-Martinez, Faming Zhang, Guoxin Zhu